APL-2 Prevents Both C3 And C5 Convertase Formation And Activity: A Potential Therapeutic For Renal Diseases
C3 Inhibition With APL-2 Targets The Underlying Disease Process Of C3G Complement Hyperactivity And Improves Proteinuria
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.